Prognostic Value of
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ therapeutic use
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Czech Republic
Disease Progression
Drug Resistance, Neoplasm
ErbB Receptors
/ genetics
Exons
Female
Genetic Predisposition to Disease
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Mutagenesis, Insertional
Phenotype
Protein Kinase Inhibitors
/ therapeutic use
Registries
Retrospective Studies
Time Factors
Treatment Outcome
Young Adult
EGFR exon-20 insertions
NSCLC
RWE
prognostic values
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
20
09
2021
revised:
18
10
2021
accepted:
19
10
2021
entrez:
4
11
2021
pubmed:
5
11
2021
medline:
16
11
2021
Statut:
ppublish
Résumé
Per literature, patients with epidermal growth factor receptor (EGFR) exon-20 insertions respond poorly to tyrosine kinase inhibitors (TKIs). This study analyzed real-world data to examine the prognostic and predictive value of these mutations. We conducted a retrospective cohort study using Czech TULUNG Registry data, with data on multiple mutation types, collected in 2011-2020. We analyzed 554 (95.85%) patients with EGFR exon-19 deletions or exon-21 L858R substitutions and 24 (4.15%) patients with exon-20 insertions who received first-line high-value therapies. We summarized clinical characteristics and outcomes in all patients and by cohort. The risk of progression was statistically significantly higher (86%) in the exon-20 insertion cohort compared to the cohort with other mutations. Although not statistically significant, the risk of death was 44% higher in patients with exon-20 insertions. Advanced NSCLC patients with rare EGFR exon-20 insertions have a high risk of progression.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Per literature, patients with epidermal growth factor receptor (EGFR) exon-20 insertions respond poorly to tyrosine kinase inhibitors (TKIs). This study analyzed real-world data to examine the prognostic and predictive value of these mutations.
PATIENTS AND METHODS
METHODS
We conducted a retrospective cohort study using Czech TULUNG Registry data, with data on multiple mutation types, collected in 2011-2020.
RESULTS
RESULTS
We analyzed 554 (95.85%) patients with EGFR exon-19 deletions or exon-21 L858R substitutions and 24 (4.15%) patients with exon-20 insertions who received first-line high-value therapies. We summarized clinical characteristics and outcomes in all patients and by cohort. The risk of progression was statistically significantly higher (86%) in the exon-20 insertion cohort compared to the cohort with other mutations. Although not statistically significant, the risk of death was 44% higher in patients with exon-20 insertions.
CONCLUSION
CONCLUSIONS
Advanced NSCLC patients with rare EGFR exon-20 insertions have a high risk of progression.
Identifiants
pubmed: 34732435
pii: 41/11/5625
doi: 10.21873/anticanres.15378
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5625-5634Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.